Granite Point Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Granite Point Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-8,000	Closed	-$1.22M	–	89
2019 Q2	$1.22M	Sell	8,000 -12,500	-61%	-$1.52M	0.08%	55
2019 Q1	$2.44M	Hold	20,500	–	–	0.24%	41
2018 Q4	$2.24M	Hold	20,500	–	–	0.45%	35
2018 Q3	$3.31M	Sell	20,500 -7,220	-26%	-$987K	0.22%	44
2018 Q2	$3.66M	Sell	27,720 -3,300	-11%	-$311K	0.33%	31
2018 Q1	$2.3M	Sell	31,020 -13,200	-30%	-$880K	0.22%	30
2017 Q4	$2.46M	Sell	44,220 -2,300	-5%	-$122K	0.24%	24
2017 Q3	$2.11M	Sell	46,520 -16,700	-26%	-$667K	0.44%	27
2017 Q2	$2.13M	Buy	63,220 +39,850	+171%	+$1.3M	0.53%	32
2017 Q1	$692K	Sell	23,370 -36,630	-61%	-$1.13M	0.21%	55
2016 Q4	$1.65M	Sell	60,000 -100,000	-63%	-$4.02M	1.31%	24
2016 Q3	$9.83M	Buy	160,000 +45,000	+39%	+$1.36M	3.84%	5
2016 Q2	$2.19M	Buy	+115,000	New	+$2.13M	0.94%	18

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Granite Point Capital Management's SRPT Position: Q3 2019 in Review

Granite Point Capital Management sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 8,000 shares — an estimated $1.22M sold.

Granite Point Capital Management first reported a position in SRPT in Q2 2016 and held it in 13 quarters. The position peaked at $9.83M in Q3 2016. 341 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

Granite Point Capital Management reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
Granite Point Capital Management sold 8,000 Sarepta Therapeutics shares in Q3 2019, an estimated $1.22M.
Granite Point Capital Management first reported a position in Sarepta Therapeutics in Q2 2016 and held it in 13 quarters.
Granite Point Capital Management's Sarepta Therapeutics position peaked at $9.83M in Q3 2016.
341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Granite Point Capital Management's 13F filing for Q3 2019, filed 30 Oct 2019.